ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1066

Biologic Drug and Anti-Drug Antibody Monitoring: All 5 TNF-Inhibitors, Infliximab, Adalimumab, Golimumab, Etanercept, Certolizumab Pegol, in 63,930 Patient Samples

Kelly Chun and Jane Yang, Labcorp, Calabasas, CA

Meeting: ACR Convergence 2023

Keywords: Anti-TNF Drugs, autoimmune diseases, Biologicals, Disease-Modifying Antirheumatic Drugs (Dmards), infliximab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1052–1081) Immunological Complications of Medical Therapy Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Biologic therapeutic drug monitoring (TDM) of TNF-inhibitor drug and anti-drug antibody provides patient-specific pharmacokinetic and immunogenic assessment. In suboptimal response, drug and anti-drug antibody concentrations discern the underlying mechanism of failure as: 1) Pharmacokinetic Insufficiency, not enough drug (low drug) 2) Mechanistic Mismatch, wrong type of drug (as evidenced by sufficiently high drug) or 3) immunogenicity (anti-drug antibodies) As such, biologic TDM informs the very different medication decisions of whether to increase the same biologic or to switch drug, in- or out-of class.

Methods: Drug (in μg/mL) and anti-drug antibody (in ng/mL) were measured by lab developed chemiluminescent immunoassays (Table 1). Of note, all drug assays measure the antibody-unbound fraction of drug when serum anti-drug antibodies are present. All anti-drug antibody assays are drug-tolerant and drug-specific as verified by a confirmatory test. Blood collection just prior to next infusion/injection is recommended because target ranges have been set by studies using trough concentrations.

Results: Serum samples from 37,165, 22,412, 1032, 2587, and 734 patients were analyzed for IFX, ADL, GOL, CTZ or ETN and corresponding anti-drug antibodies. Distribution of drug levels (Figure 1) demonstrates that even in the absence of immunogenicity, many patients may be subtherapeutic when using reasonable, if not well-established, therapeutic targets of 3 for IFX, 5 for ADL, 3 for GOL, 20 for CTZ, and 3 for ETN. Immunogenicity rates were 45.2%, 39.4%, 4.4%, 67.6% and 72.3% for IFX, ADL, GOL, CTZ and ETN, respectively (Table 1). High immunogenicity of ETN and CTZ may be explained by their uniqueness as fusion and pegylated molecules, respectively. Figure 2 demonstrates the relationship between free drug and anti-drug antibody. Analysis of this inverse relationship yielded cut-points for titer designations of low, intermediate, and high for anti-IFX, anti-ADL, and anti-CTZ (Table 1). Of note, ETN alone lacked this inverse relationship. Anti-ETN, even in high titer, had no effect on concomitant ETN. Anti-CTZ were the highest numerically, but many may be non-neutralizing antibodies against pegol where only >5000 appears to be impactful. As a good rule, anti-drug antibodies should be interpreted in the context of the concomitant free drug trough concentration.

Conclusion: Here, we report TNF-inhibitor and their anti-drug antibody levels in >60,000 patients. Though clinical histories and blood collection timing are not known, Figure 1 showed that many patients may have insufficient drug levels. Observed immunogenicity rates to IFX, ADL, CTZ and ETN were high and all anti-drug antibodies except anti-ETN adversely affect free drug levels. Numeric antibody results should be interpreted with the help of titer designations (low/high) by the laboratory because low titer antibodies have less impact on drug levels and may be transient or reversible whereas high titers with nil or very low drug indicate refractory immunogenicity. In this way, biologic TDM elucidates the mechanism of suboptimal response and should be used to optimize drug efficacy and longevity by informing and expediting adjustments to medication.

Supporting image 1

Table 1. Biologic TNF-Inhibitor Drug and Anti-Drug Antibody Assays: Performance Characteristics and Interpretation

Supporting image 2

Figure 1. Distribution of Biologic Drug Concentrations in Anti-Drug Antibody-Negative Samples

Supporting image 3

Figure 2. The Relationship between Biologic Drug and Anti-Drug Antibody Concentrations


Disclosures: K. Chun: None; J. Yang: None.

To cite this abstract in AMA style:

Chun K, Yang J. Biologic Drug and Anti-Drug Antibody Monitoring: All 5 TNF-Inhibitors, Infliximab, Adalimumab, Golimumab, Etanercept, Certolizumab Pegol, in 63,930 Patient Samples [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/biologic-drug-and-anti-drug-antibody-monitoring-all-5-tnf-inhibitors-infliximab-adalimumab-golimumab-etanercept-certolizumab-pegol-in-63930-patient-samples/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/biologic-drug-and-anti-drug-antibody-monitoring-all-5-tnf-inhibitors-infliximab-adalimumab-golimumab-etanercept-certolizumab-pegol-in-63930-patient-samples/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology